Search Results - "Berille, J."

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis by Ferreira, A.R., Di Meglio, A., Pistilli, B., Gbenou, A.S., El-Mouhebb, M., Dauchy, S., Charles, C., Joly, F., Everhard, S., Lambertini, M., Coutant, C., Cottu, P., Lerebours, F., Petit, T., Dalenc, F., Rouanet, P., Arnaud, A., Martin, A., Berille, J., Ganz, P.A., Partridge, A.H., Delaloge, S., Michiels, S., Andre, F., Vaz-Luis, I.

“…In early breast cancer (BC), there has been a trend to escalate endocrine therapy (ET) and to de-escalate chemotherapy (CT). However, the impact of ET versus…”
Get full text

Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients by Rezai, Keyvan, Urien, S., Isambert, N., Roche, H., Dieras, V., Berille, J., Bonneterre, J., Brain, E., Lokiec, F.

“…Purpose The objectives of this study were to investigate the pharmacokinetics of intra-venous vinorelbine combined with lapatinib as well as the effect of…”
Get full text

8000 ORAL Results of the GYNECO 02 Study, a FNCLCC Phase III Trial Comparing Hysterectomy Versus No Hysterectomy in Patients With a (Clinical and Radiological) Complete Response After Chemoradiation Therapy in IB2/II Stage Cervical Cancer by Morice, P, Rey, A, Rouanet, P, Romestaing, P, Houvenaeghel, G, Boulanger, J.C, Leveque, J, Cowen, D, Berille, J, Haie-Meder, C

Get full text

Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer by Zalcberg, J, Millward, M, Bishop, J, McKeage, M, Zimet, A, Toner, G, Friedlander, M, Barter, C, Rischin, D, Loret, C, James, R, Bougan, N, Berille, J

“…Docetaxel (Taxotere, Rhone-Poulenc Rorer, Antony, France) and cisplatin are two of the most active single agents used in the treatment of non-small-cell lung…”
Get more information

Docetaxel (taxotere®) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer by Le Chevalier, T, Monnier, A, Douillard, J.Y, Ruffie, P, Sun, X.S, Belli, L, Ibrahim, N, Bougon, N, Bérille, J

“…The activity of the combination of intravenous docetaxel 75 mg/m 2 plus cisplatin 100 mg/m 2 administered every 3 weeks for 3 cycles then every 6 weeks was…”
Get full text

Phase i dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (dl-d2-d3) in patients with refractory solid tumors by CAMPONE, M, ISAMBERT, N, BOURBOULOUX, E, MAURY, S, MONIN-BAROILLE, P, BERILLE, J, FUMOLEAU, P

“…SR271425 is a novel DNA-binding cytotoxic agent with a broad spectrum of antitumor activity in preclinical models,across a variety of the schedule of…”
Get full text

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer by Fossella, F V, Lee, J S, Berille, J, Hong, W K

“…Six phase II studies have been conducted in the United States and Europe using docetaxel (Taxotere; Rhone-Poulenc Rorer, Antony, France) for advanced non-small…”
Get more information

A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer by Bennouna, J, Monnier, A, Rivière, A, Milleron, B, Lemarie, E, Trillet-Lenoir, V, Soussan-Lazard, K, Berille, J, Douillard, J.Y

“…A phase II study was conducted to determine the efficacy and the safety of docetaxel combined with vinorelbine as first-line chemotherapy in patients with…”
Get full text

Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer by Le Chevalier, T, Bérille, J, Zalcberg, J R, Millward, M J, Monnier, A, Douillard, J Y, McKeage, M J, James, R, Soulas, F, Loret, C, Bougon, N, Bizzari, J P

“…Cisplatin-based chemotherapy is effective in non-small cell lung cancer (NSCLC), although it prolongs survival only modestly. Single-agent docetaxel (Taxotere;…”
Get more information

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice by Mattson, K, Bosquee, L, Dabouis, G, Le Groumellec, A, Pujol, J.L, Marien, S, Stupp, R, Douillard, J.Y, Brägas, B, Berille, J, Olivares, R, Le Chevalier, T

“…The purpose of this study was to evaluate the efficacy and safety of docetaxel as first- and second-line chemotherapy for advanced non-small cell lung cancer…”
Get full text

A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer by Cotto, C., Berille, J., Souquet, P.J., Riou, R., Croisile, B., Turjman, F., Giroux, B., Brune, J., Trillet-Lenoir, V.

“…A phase II study was conducted in order to determine the feasibility and toxicity of cisplatin combined with the nitrosourea fotemustine in central nervous…”
Get full text

Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer : the Canadian experience by LATREILLE, J, GELMON, K. A, HIRSH, V, LABERGE, F, MAKSYMIUK, A. W, SHEPHERD, F. A, DELORME, F, BERILLE, J

“…We performed a Phase II trial to evaluate the activity and tolerability of docetaxel as a single agent in the treatment of advanced non-small cell lung cancer…”
Get full text

Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy by SHEPHERD, F. A, DANCEY, J, COUGHLIN, S, YONG KIM, BERILLE, J, RAMLAU, R, MATTSON, K, GRALLA, R, O'ROURKE, M, LEVITAN, N, GRESSOT, L, VINCENT, M, BURKES, R

“…To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung…”
Get full text

Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer by Mattson, Karin, Vansteenkiste, Johan, Stupp, Roger, Bargetzi, Mario, Saarinen, Antti, Jekunen, Antti, Fillet, Georges, Teixeira, Maria, Gatzemeier, Ulrich, Olivares, Robert, Soussan-Lazard, Karen, Bérille, Jocelyne

“…The objective of this study was to evaluate a regimen of full doses of docetaxel and cisplatin, using an alternating schedule, as first-line therapy for…”
Get full text

Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial by Rivière, A, Le Cesne, A, Berille, J, Baio, S, Le Chevalier, T

“…Fotemustine is a new nitrosourea derivative whose activity has been demonstrated on metastatic melanoma with specific activity on brain metastases and also on…”
Get more information

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer by Pujol, J L, Monnier, A, Berille, J, Cerrina, M L, Douillard, J Y, Rivière, A, Grandgirard, A, Gouva, S, Bizzari, J P, Le Chevalier, T

“…A phase II study was designed to evaluate objective response rate and toxicity of fotemustine as single-drug chemotherapy in non-small-cell lung cancer…”
Get full text

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC) by Roszkowski, Kazimierz, Pluzanska, Anna, Krzakowski, Maciej, Smith, Alexander Peter, Saigi, Eugeni, Aasebo, Ulf, Parisi, Annamaria, Pham Tran, Ngoc, Olivares, Robert, Berille, Jocelyne

“…This was an open-label randomized Phase III study of 207 patients with either unresectable or metastatic non-small cell lung cancer (NSCLC) who were treated…”
Get full text

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis by Ferreira, A R, Di Meglio, A, Pistilli, B, Gbenou, A S, El-Mouhebb, M, Dauchy, S, Charles, C, Joly, F, Everhard, S, Lambertini, M, Coutant, C, Cottu, P, Lerebours, F, Petit, T, Dalenc, F, Rouanet, P, Arnaud, A, Martin, A, Berille, J, Ganz, P A, Partridge, A H, Delaloge, S, Michiels, S, Andre, F, Vaz-Luis, I

“…In early breast cancer (BC), there has been a trend to escalate endocrine therapy (ET) and to de-escalate chemotherapy (CT). However, the impact of ET versus…”
Get full text

Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16 by Deutsch, E., Lemanski, C., Paris, E., Delarochefordiere, A., Martel-Lafay, I., Rio, E., Miglianico, L., Becouarn, Y., Pignon, J., Berille, J., Ezra, P., Azria, D.

“…Abstract only…”
Get full text

Docetaxel-estramustine in high-risk localized prostate cancer: First results of the French Genitourinary Tumor Group phase III trial (GETUG 12) by Fizazi, K., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., Priou, F., Ferrero, J., Houede, N., Mourey, L., Theodore, C., Krakowski, I., Berdah, J. F., Baciuchka, M., Kerbrat, P., Davin, J., Berille, J., Habibian, M., Ichante, J., Laplanche, A., Culine, S.

“…Abstract only…”
Get full text